| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PEO1 |
| Uniprot No | Q96RR1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-684aa |
| 氨基酸序列 | APGPPRRRYRKETLQALDMPVLPVTATEIRQYLRGHGIPFQDGHSCLRALSPFAESSQLKGQTGVTTSFSLFIDKTTGHFLCMTSLAEGSWEDFQASVEGRGDGAREGFLLSKAPEFEDSEEVRRIWNRAIPLWELPDQEEVQLADTMFGLTKVTDDTLKRFSVRYLRPARSLVFPWFSPGGSGLRGLKLLEAKCQGDGVSYEETTIPRPSAYHNLFGLPLISRRDAEVVLTSRELDSLALNQSTGLPTLTLPRGTTCLPPALLPYLEQFRRIVFWLGDDLRSWEAAKLFARKLNPKRCFLVRPGDQQPRPLEALNGGFNLSRILRTALPAWHKSIVSFRQLREEVLGELSNVEQAAGLRWSRFPDLNRILKGHRKGELTVFTGPTGSGKTTFISEYALDLCSQGVNTLWGSFEISNVRLARVMLTQFAEGRLEDQLDKYDHWADRFEDLPLYFMTFHGQQSIRTVIDTMQHAVYVYDICHVIIDNLQFMMGHEQLSTDRIAAQDYIIGVFRKFATDNNCHVTLVIHPRKEDDDKELQTASIFGSAKASQEADNVLILQDRKLVTGPGKRYLQVSKNRFDGDVGVFPLEFNKNSLTFSIPPKNKARLKKIKDDTGPVAKKPSSGKKGATTQNSEICSGQAPTPDQPDTSKRSK |
| 预测分子量 | 75.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PEO1重组蛋白研究的假设性参考文献示例(基于常见研究方向推测，实际文献需通过数据库验证)：
---
1. **标题**：*Recombinant BRCA1 expression restores olaparib sensitivity in PEO1 ovarian cancer cells*
**作者**：Smith A, et al.
**摘要**：研究通过重组BRCA1蛋白在BRCA2突变型PEO1细胞中的表达，发现其能够部分恢复同源重组修复功能，逆转对PARP抑制剂奥拉帕尼的耐药性，为联合治疗提供理论依据。
2. **标题**：*Targeting PI3K/AKT pathway with recombinant PTEN in PEO1 cells*
**作者**：Chen L, et al.
**摘要**：通过腺病毒载体在PEO1细胞中表达重组PTEN蛋白，显著抑制PI3K/AKT信号通路活性，诱导细胞凋亡并增强顺铂化疗敏感性，提示PTEN重组蛋白的潜在治疗价值。
3. **标题**：*Recombinant p53 modulates chemoresistance in PEO1 ovarian carcinoma models*
**作者**：Doe J, et al.
**摘要**：利用慢病毒系统在p53缺陷的PEO1细胞中表达重组野生型p53蛋白，结果显示细胞周期阻滞和凋亡增加，同时降低紫杉醇耐药性，支持p53修复策略的可行性。
4. **标题**：*Engineered recombinant TRAIL protein induces apoptosis in PEO1 cells via death receptor activation*
**作者**：Kim S, et al.
**摘要**：设计一种新型重组TRAIL蛋白变体，在PEO1细胞中通过激活死亡受体DR4/DR5显著诱导caspase依赖性凋亡，且对正常细胞毒性较低，为靶向治疗提供新候选分子。
---
**注意**：以上为模拟文献，实际研究需查阅PubMed、Web of Science等数据库，关键词组合如“PEO1 recombinant protein”、“PEO1 gene expression”或结合具体靶点(如BRCA1. PTEN)。建议用户通过机构访问SCI数据库获取真实文献。
The PEO1 recombinant protein is derived from the PEO1 cell line, a well-characterized human ovarian cancer model originally isolated from a malignant effusion of a patient with progressive ovarian adenocarcinoma. This cell line is particularly notable for harboring a homozygous BRCA2 mutation (c.5193-5194delCA), rendering it deficient in homologous recombination repair (HRR), a key DNA damage response pathway. This genetic defect makes PEO1 cells highly relevant for studying synthetic lethality mechanisms, particularly in the context of PARP inhibitor sensitivity, which exploits HRR-deficient cancers.
Recombinant proteins derived from PEO1 cells are engineered to express specific cancer-associated proteins or mutant variants for functional studies. These proteins are typically produced using heterologous expression systems (e.g., E. coli, HEK293. or insect cells) to ensure high purity and yield. The production process involves cloning target genes from PEO1 cells into expression vectors, followed by transfection, protein purification, and characterization using techniques like Western blotting and mass spectrometry.
PEO1 recombinant proteins serve as critical tools for investigating ovarian cancer biology, drug resistance mechanisms, and therapeutic target validation. They are widely used in enzymatic assays, protein-protein interaction studies, and high-throughput drug screening. Notably, proteins related to DNA repair pathways (e.g., PARP, BRCA1/2 mutants) from this cell line have been instrumental in advancing precision oncology, particularly in developing biomarkers for PARP inhibitor response. Their clinical relevance extends to modeling acquired chemoresistance, as PEO1 derivatives can develop platinum resistance through secondary BRCA2 reversion mutations.
×
